Table of Contents 1 Report Overview 1.1 Study Scope 1.2 Key Market Segments 1.3 Players Covered: Ranking by Neuroendocrine Carcinoma Treatment Revenue 1.4 Market Analysis by Type 1.4.1 Global Neuroendocrine Carcinoma Treatment Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 Somatostatin Analogs 1.4.3 Targeted Therapy 1.4.4 Chemotherapy 1.5 Market by Application 1.5.1 Global Neuroendocrine Carcinoma Treatment Market Share by Application: 2020 VS 2026 1.5.2 Hospitals 1.5.3 Clinics 1.5.4 Oncology Centers 1.5.5 Ambulatory Surgical Centers 1.5.6 Others 1.6 Study Objectives 1.7 Years Considered 2 Global Growth Trends by Regions 2.1 Neuroendocrine Carcinoma Treatment Market Perspective (2015-2026) 2.2 Neuroendocrine Carcinoma Treatment Growth Trends by Regions 2.2.1 Neuroendocrine Carcinoma Treatment Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Neuroendocrine Carcinoma Treatment Historic Market Share by Regions (2015-2020) 2.2.3 Neuroendocrine Carcinoma Treatment Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porter’s Five Forces Analysis 2.3.5 Neuroendocrine Carcinoma Treatment Market Growth Strategy 2.3.6 Primary Interviews with Key Neuroendocrine Carcinoma Treatment Players (Opinion Leaders) 3 Competition Landscape by Key Players 3.1 Global Top Neuroendocrine Carcinoma Treatment Players by Market Size 3.1.1 Global Top Neuroendocrine Carcinoma Treatment Players by Revenue (2015-2020) 3.1.2 Global Neuroendocrine Carcinoma Treatment Revenue Market Share by Players (2015-2020) 3.1.3 Global Neuroendocrine Carcinoma Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.2 Global Neuroendocrine Carcinoma Treatment Market Concentration Ratio 3.2.1 Global Neuroendocrine Carcinoma Treatment Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by Neuroendocrine Carcinoma Treatment Revenue in 2019 3.3 Neuroendocrine Carcinoma Treatment Key Players Head office and Area Served 3.4 Key Players Neuroendocrine Carcinoma Treatment Product Solution and Service 3.5 Date of Enter into Neuroendocrine Carcinoma Treatment Market 3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026) 4.1 Global Neuroendocrine Carcinoma Treatment Historic Market Size by Type (2015-2020) 4.2 Global Neuroendocrine Carcinoma Treatment Forecasted Market Size by Type (2021-2026) 5 Neuroendocrine Carcinoma Treatment Breakdown Data by Application (2015-2026) 5.1 Global Neuroendocrine Carcinoma Treatment Market Size by Application (2015-2020) 5.2 Global Neuroendocrine Carcinoma Treatment Forecasted Market Size by Application (2021-2026) 6 North America 6.1 North America Neuroendocrine Carcinoma Treatment Market Size (2015-2020) 6.2 Neuroendocrine Carcinoma Treatment Key Players in North America (2019-2020) 6.3 North America Neuroendocrine Carcinoma Treatment Market Size by Type (2015-2020) 6.4 North America Neuroendocrine Carcinoma Treatment Market Size by Application (2015-2020) 7 Europe 7.1 Europe Neuroendocrine Carcinoma Treatment Market Size (2015-2020) 7.2 Neuroendocrine Carcinoma Treatment Key Players in Europe (2019-2020) 7.3 Europe Neuroendocrine Carcinoma Treatment Market Size by Type (2015-2020) 7.4 Europe Neuroendocrine Carcinoma Treatment Market Size by Application (2015-2020) (2015-2020) (2015-2020) (2015-2020) (2015-2020) 8 Key Players Profiles 8.1 Pfizer 8.1.1 Pfizer Company Details 8.1.2 Pfizer Business Overview and Its Total Revenue 8.1.3 Pfizer Neuroendocrine Carcinoma Treatment Introduction 8.1.4 Pfizer Revenue in Neuroendocrine Carcinoma Treatment Business (2015-2020)) 8.1.5 Pfizer Recent Development 8.2 Novartis 8.2.1 Novartis Company Details 8.2.2 Novartis Business Overview and Its Total Revenue 8.2.3 Novartis Neuroendocrine Carcinoma Treatment Introduction 8.2.4 Novartis Revenue in Neuroendocrine Carcinoma Treatment Business (2015-2020) 8.2.5 Novartis Recent Development 8.3 Chiasma, Inc. 8.3.1 Chiasma, Inc. Company Details 8.3.2 Chiasma, Inc. Business Overview and Its Total Revenue 8.3.3 Chiasma, Inc. Neuroendocrine Carcinoma Treatment Introduction 8.3.4 Chiasma, Inc. Revenue in Neuroendocrine Carcinoma Treatment Business (2015-2020) 8.3.5 Chiasma, Inc. Recent Development 8.4 Ipsen 8.4.1 Ipsen Company Details 8.4.2 Ipsen Business Overview and Its Total Revenue 8.4.3 Ipsen Neuroendocrine Carcinoma Treatment Introduction 8.4.4 Ipsen Revenue in Neuroendocrine Carcinoma Treatment Business (2015-2020) 8.4.5 Ipsen Recent Development 8.5 AbbVie 8.5.1 AbbVie Company Details 8.5.2 AbbVie Business Overview and Its Total Revenue 8.5.3 AbbVie Neuroendocrine Carcinoma Treatment Introduction 8.5.4 AbbVie Revenue in Neuroendocrine Carcinoma Treatment Business (2015-2020) 8.5.5 AbbVie Recent Development 8.6 Bausch Health 8.6.1 Bausch Health Company Details 8.6.2 Bausch Health Business Overview and Its Total Revenue 8.6.3 Bausch Health Neuroendocrine Carcinoma Treatment Introduction 8.6.4 Bausch Health Revenue in Neuroendocrine Carcinoma Treatment Business (2015-2020) 8.6.5 Bausch Health Recent Development 8.7 Jubilant 8.7.1 Jubilant Company Details 8.7.2 Jubilant Business Overview and Its Total Revenue 8.7.3 Jubilant Neuroendocrine Carcinoma Treatment Introduction 8.7.4 Jubilant Revenue in Neuroendocrine Carcinoma Treatment Business (2015-2020) 8.7.5 Jubilant Recent Development 8.8 Teva Pharmaceutical Industries Ltd. 8.8.1 Teva Pharmaceutical Industries Ltd. Company Details 8.8.2 Teva Pharmaceutical Industries Ltd. Business Overview and Its Total Revenue 8.8.3 Teva Pharmaceutical Industries Ltd. Neuroendocrine Carcinoma Treatment Introduction 8.8.4 Teva Pharmaceutical Industries Ltd. Revenue in Neuroendocrine Carcinoma Treatment Business (2015-2020) 8.8.5 Teva Pharmaceutical Industries Ltd. Recent Development 8.9 Roche 8.9.1 Roche Company Details 8.9.2 Roche Business Overview and Its Total Revenue 8.9.3 Roche Neuroendocrine Carcinoma Treatment Introduction 8.9.4 Roche Revenue in Neuroendocrine Carcinoma Treatment Business (2015-2020) 8.9.5 Roche Recent Development 8.10 Mateon 8.10.1 Mateon Company Details 8.10.2 Mateon Business Overview and Its Total Revenue 8.10.3 Mateon Neuroendocrine Carcinoma Treatment Introduction 8.10.4 Mateon Revenue in Neuroendocrine Carcinoma Treatment Business (2015-2020) 8.10.5 Mateon Recent Development 9 Analyst's Viewpoints/Conclusions 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.2 Data Source 10.2 Disclaimer 10.3 Author Details

List of Tables Table 1. Neuroendocrine Carcinoma Treatment Key Market Segments Table 2. Key Players Covered: Ranking by Neuroendocrine Carcinoma Treatment Revenue Table 3. Ranking of Global Top Neuroendocrine Carcinoma Treatment Manufacturers by Revenue (US$ Million) in 2019 Table 4. Global Neuroendocrine Carcinoma Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026 Table 5. Key Players of Somatostatin Analogs Table 6. Key Players of Targeted Therapy Table 7. Key Players of Chemotherapy Table 8. Global Neuroendocrine Carcinoma Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026 Table 9. Global Neuroendocrine Carcinoma Treatment Market Size by Regions (US$ Million): 2020 VS 2026 Table 10. Global Neuroendocrine Carcinoma Treatment Market Size by Regions (2015-2020) (US$ Million) Table 11. Global Neuroendocrine Carcinoma Treatment Market Share by Regions (2015-2020) Table 12. Global Neuroendocrine Carcinoma Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million) Table 13. Global Neuroendocrine Carcinoma Treatment Market Share by Regions (2021-2026) Table 14. Market Top Trends Table 15. Key Drivers: Impact Analysis Table 16. Key Challenges Table 17. Neuroendocrine Carcinoma Treatment Market Growth Strategy Table 18. Main Points Interviewed from Key Neuroendocrine Carcinoma Treatment Players Table 19. Global Neuroendocrine Carcinoma Treatment Revenue by Players (2015-2020) (Million US$) Table 20. Global Neuroendocrine Carcinoma Treatment Market Share by Players (2015-2020) Table 21. Global Top Neuroendocrine Carcinoma Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuroendocrine Carcinoma Treatment as of 2019) Table 22. Global Neuroendocrine Carcinoma Treatment by Players Market Concentration Ratio (CR5 and HHI) Table 23. Key Players Headquarters and Area Served Table 24. Key Players Neuroendocrine Carcinoma Treatment Product Solution and Service Table 25. Date of Enter into Neuroendocrine Carcinoma Treatment Market Table 26. Mergers & Acquisitions, Expansion Plans Table 27. Global Neuroendocrine Carcinoma Treatment Market Size by Type (2015-2020) (Million US$) Table 28. Global Neuroendocrine Carcinoma Treatment Market Size Share by Type (2015-2020) Table 29. Global Neuroendocrine Carcinoma Treatment Revenue Market Share by Type (2021-2026) Table 30. Global Neuroendocrine Carcinoma Treatment Market Size Share by Application (2015-2020) Table 31. Global Neuroendocrine Carcinoma Treatment Market Size by Application (2015-2020) (Million US$) Table 32. Global Neuroendocrine Carcinoma Treatment Market Size Share by Application (2021-2026) Table 33. North America Key Players Neuroendocrine Carcinoma Treatment Revenue (2019-2020) (Million US$) Table 34. North America Key Players Neuroendocrine Carcinoma Treatment Market Share (2019-2020) Table 35. North America Neuroendocrine Carcinoma Treatment Market Size by Type (2015-2020) (Million US$) Table 36. North America Neuroendocrine Carcinoma Treatment Market Share by Type (2015-2020) Table 37. North America Neuroendocrine Carcinoma Treatment Market Size by Application (2015-2020) (Million US$) Table 38. North America Neuroendocrine Carcinoma Treatment Market Share by Application (2015-2020) Table 39. Europe Key Players Neuroendocrine Carcinoma Treatment Revenue (2019-2020) (Million US$) Table 40. Europe Key Players Neuroendocrine Carcinoma Treatment Market Share (2019-2020) Table 41. Europe Neuroendocrine Carcinoma Treatment Market Size by Type (2015-2020) (Million US$) Table 42. Europe Neuroendocrine Carcinoma Treatment Market Share by Type (2015-2020) Table 43. Europe Neuroendocrine Carcinoma Treatment Market Size by Application (2015-2020) (Million US$) Table 44. Europe Neuroendocrine Carcinoma Treatment Market Share by Application (2015-2020) Table 45. Pfizer Company Details Table 46. Pfizer Business Overview Table 47. Pfizer Product Table 48. Pfizer Revenue in Neuroendocrine Carcinoma Treatment Business (2015-2020) (Million US$) Table 49. Pfizer Recent Development Table 50. Novartis Company Details Table 51. Novartis Business Overview Table 52. Novartis Product Table 53. Novartis Revenue in Neuroendocrine Carcinoma Treatment Business (2015-2020) (Million US$) Table 54. Novartis Recent Development Table 55. Chiasma, Inc. Company Details Table 56. Chiasma, Inc. Business Overview Table 57. Chiasma, Inc. Product Table 58. Chiasma, Inc. Revenue in Neuroendocrine Carcinoma Treatment Business (2015-2020) (Million US$) Table 59. Chiasma, Inc. Recent Development Table 60. Ipsen Company Details Table 61. Ipsen Business Overview Table 62. Ipsen Product Table 63. Ipsen Revenue in Neuroendocrine Carcinoma Treatment Business (2015-2020) (Million US$) Table 64. Ipsen Recent Development Table 65. AbbVie Company Details Table 66. AbbVie Business Overview Table 67. AbbVie Product Table 68. AbbVie Revenue in Neuroendocrine Carcinoma Treatment Business (2015-2020) (Million US$) Table 69. AbbVie Recent Development Table 70. Bausch Health Company Details Table 71. Bausch Health Business Overview Table 72. Bausch Health Product Table 73. Bausch Health Revenue in Neuroendocrine Carcinoma Treatment Business (2015-2020) (Million US$) Table 74. Bausch Health Recent Development Table 75. Jubilant Company Details Table 76. Jubilant Business Overview Table 77. Jubilant Product Table 78. Jubilant Revenue in Neuroendocrine Carcinoma Treatment Business (2015-2020) (Million US$) Table 79. Jubilant Recent Development Table 80. Teva Pharmaceutical Industries Ltd. Business Overview Table 81. Teva Pharmaceutical Industries Ltd. Product Table 82. Teva Pharmaceutical Industries Ltd. Company Details Table 83. Teva Pharmaceutical Industries Ltd. Revenue in Neuroendocrine Carcinoma Treatment Business (2015-2020) (Million US$) Table 84. Teva Pharmaceutical Industries Ltd. Recent Development Table 85. Roche Company Details Table 86. Roche Business Overview Table 87. Roche Product Table 88. Roche Revenue in Neuroendocrine Carcinoma Treatment Business (2015-2020) (Million US$) Table 89. Roche Recent Development Table 90. Mateon Company Details Table 91. Mateon Business Overview Table 92. Mateon Product Table 93. Mateon Revenue in Neuroendocrine Carcinoma Treatment Business (2015-2020) (Million US$) Table 94. Mateon Recent Development Table 95. Research Programs/Design for This Report Table 96. Key Data Information from Secondary Sources Table 97. Key Data Information from Primary Sources List of Figures Figure 1. Global Neuroendocrine Carcinoma Treatment Market Share by Type: 2020 VS 2026 Figure 2. Somatostatin Analogs Features Figure 3. Targeted Therapy Features Figure 4. Chemotherapy Features Figure 5. Global Neuroendocrine Carcinoma Treatment Market Share by Application: 2020 VS 2026 Figure 6. Hospitals Case Studies Figure 7. Clinics Case Studies Figure 8. Oncology Centers Case Studies Figure 9. Ambulatory Surgical Centers Case Studies Figure 10. Others Case Studies Figure 11. Neuroendocrine Carcinoma Treatment Report Years Considered Figure 12. Global Neuroendocrine Carcinoma Treatment Market Size YoY Growth 2015-2026 (US$ Million) Figure 13. Global Neuroendocrine Carcinoma Treatment Market Share by Regions: 2020 VS 2026 Figure 14. Global Neuroendocrine Carcinoma Treatment Market Share by Regions (2021-2026) Figure 15. Porter's Five Forces Analysis Figure 16. Global Neuroendocrine Carcinoma Treatment Market Share by Players in 2019 Figure 17. Global Top Neuroendocrine Carcinoma Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuroendocrine Carcinoma Treatment as of 2019 Figure 18. The Top 10 and 5 Players Market Share by Neuroendocrine Carcinoma Treatment Revenue in 2019 Figure 19. North America Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2015-2020) (Million US$) Figure 20. Europe Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2015-2020) (Million US$) Figure 21. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018 Figure 22. Pfizer Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2015-2020) Figure 23. Novartis Total Revenue (US$ Million): 2019 Compared with 2018 Figure 24. Novartis Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2015-2020) Figure 25. Chiasma, Inc. Total Revenue (US$ Million): 2019 Compared with 2018 Figure 26. Chiasma, Inc. Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2015-2020) Figure 27. Ipsen Total Revenue (US$ Million): 2019 Compared with 2018 Figure 28. Ipsen Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2015-2020) Figure 29. AbbVie Total Revenue (US$ Million): 2019 Compared with 2018 Figure 30. AbbVie Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2015-2020) Figure 31. Bausch Health Total Revenue (US$ Million): 2019 Compared with 2018 Figure 32. Bausch Health Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2015-2020) Figure 33. Jubilant Total Revenue (US$ Million): 2019 Compared with 2018 Figure 34. Jubilant Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2015-2020) Figure 35. Teva Pharmaceutical Industries Ltd. Total Revenue (US$ Million): 2019 Compared with 2018 Figure 36. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2015-2020) Figure 37. Roche Total Revenue (US$ Million): 2019 Compared with 2018 Figure 38. Roche Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2015-2020) Figure 39. Mateon Total Revenue (US$ Million): 2019 Compared with 2018 Figure 40. Mateon Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2015-2020) Figure 41. Bottom-up and Top-down Approaches for This Report Figure 42. Data Triangulation

Pfizer Novartis Chiasma, Inc. Ipsen AbbVie Bausch Health Jubilant Teva Pharmaceutical Industries Ltd. Roche Mateon